Cardiff Oncology (CRDF) Profit After Tax (2011 - 2026)

Cardiff Oncology has reported Profit After Tax for 15 years, with the latest figure at -$7.2 million in Q4 2025.

• Quarterly Profit After Tax rose 38.78% year-over-year to -$7.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$45.9 million (down 0.92% YoY) and the FY2025 annual result came in at -$45.9 million, down 0.92% from the prior year.
• Profit After Tax advanced to -$7.2 million in Q4 2025 per CRDF's latest filing, from -$11.3 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$5.2 million in Q1 2021 and troughed at -$13.9 million in Q2 2025.
• A 5-year average of -$10.0 million and a median of -$10.2 million in 2022 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2022 and 2025: Profit After Tax plunged 112.26% in 2022, then surged 38.78% in 2025.
• Over 5 years, Profit After Tax stood at -$9.4 million in 2021, then advanced by 7.89% to -$8.7 million in 2022, then dropped by 7.36% to -$9.3 million in 2023, then fell by 26.24% to -$11.8 million in 2024, then soared by 38.78% to -$7.2 million in 2025.
• According to Business Quant data, Profit After Tax over the past three periods registered -$7.2 million, -$11.3 million, and -$13.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.